ADOC.PA▲
Adocia regains global rights to M1Pram as Sanofi exclusivity expires
Adocia announced the expiration of Sanofi's three-year exclusive right to negotiate a partnership for M1Pram, a fixed combination of insulin and amylin analogs for type 1 diabetes. The exclusivity was granted in July 2023 in return for a payment of €10 million. Adocia now retains global rights to M1Pram and has put its development on hold while it evaluates the path forward as the type 1 diabetes treatment landscape evolves. The company is focusing on its metabolic peptide delivery platforms, particularly BioChaperone. In a Phase 2a trial, M1Pram demonstrated a significant reduction in body weight of 5.56 kg for participants with a BMI over 30 kg/m² after 16 weeks compared to insulin lispro, along with a 21% reduction in prandial insulin doses while maintaining glycemic control without increasing hypoglycemia risk.